Pharma rush into obesity

The hottest part of the drug industry right now is not cancer or rare disease. It is body weight, where one 2026 pipeline survey counts more than 80 companies and more than 100 drug programs chasing the same patients, doctors, and insurers. (delveinsight.com) That rush starts with the size of the problem. The World Health Organization says 890 million adults were living with obesity in 2022, and worldwide adult obesity has more than doubled since 1990. (who.int) In the United States alone, the National Institute of Diabetes and Digestive and Kidney Diseases says obesity affects more than 4 in 10 adults. The Centers for Disease Control and Prevention says the 2023 adult obesity maps showed prevalence at or above 35 percent in 23 states, up from 19 states in 2022. (niddk.nih.gov) (cdc.gov) Drugmakers are piling in because the first wave already proved people will use these medicines at scale. Novo Nordisk told investors in its 2025 annual report that demand for obesity treatment was so large it “surprised even us,” after Wegovy turned obesity into a consumer market as well as a medical one. (sec.gov) The basic science is simple enough to explain over coffee. Many of the new drugs copy gut hormones, which are chemical messages your body sends after you eat, and those messages can make people feel less hungry or full sooner. (niddk.nih.gov) The first big winners were weekly shots. The Food and Drug Administration label for Wegovy lists it for chronic weight management, and the label for Zepbound does the same, which gave doctors two branded blockbusters with broad obesity use. (accessdata.fda.gov 1) (accessdata.fda.gov 2) Now companies are trying to build second-generation versions that are easier to take or hit more than one pathway at once. Novo Nordisk said in June 2025 that both injectable and oral versions of its experimental drug amycretin would move straight to phase 3 trials for weight management after talks with regulators. (prnewswire.com) Another target getting fresh attention is amylin, a hormone signal that also helps tell the brain a meal is over. Nature reported in 2025 that drug developers were reviving amylin-based obesity medicines because they may cut weight with a different side-effect profile than the first generation of gut-hormone drugs. (nature.com 1) (nature.com 2) The market is widening in another way too: these drugs are starting to win labels beyond weight itself. In December 2024, the Food and Drug Administration approved Zepbound as the first medication for moderate to severe obstructive sleep apnea in adults with obesity, which means obesity drugs can now be sold partly as treatments for complications caused by obesity. (fda.gov) That is why the pipeline looks crowded even after two companies got such a big head start. Once a medicine can be pitched as a weekly shot, a daily pill, or a treatment for obesity-linked conditions like sleep apnea, dozens of rivals can argue they are not late to the party, just aiming at a different door. (delveinsight.com) (fda.gov) The next fight is not about proving obesity is a drug market. The next fight is over who can make the pill that is easier to manufacture, easier to reimburse, and easy enough for millions of people to stay on for years instead of months. (novonordisk.com) (prnewswire.com)